fospropofol

Trade name: lusedra

Small moleculeapproved

Approved

Dec 8, 2008

Fospropofol (INN), often used as the disodium salt is an intravenous sedative-hypnotic agent. It is currently approved for use in sedation of adult patients undergoing diagnostic or therapeutic procedures such as endoscopy. — Wikipedia

Clinical trial activity

25 trials · 17 clinical orgs · 1 marketing orgs

Phase 1
3
Phase 2
10
Phase 3
8
Phase 4
7

Earliest trial started Jun 1, 2002 (NCT00209521)

Timeline

2000s

  1. Jan 1, 2002

    Eisai — Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2004

    Eisai — Earliest Phase 3 Sponsor(trial)

  3. Dec 8, 2008

    Earliest FDA Approval

  4. Dec 8, 2008

    Eisai — Marketing Organization

2010s

  1. Jan 1, 2010

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Approval history

  • approvedDec 8, 2008

Chemistry & pharmacology

Loading structure…

SMILES

CC(C)c1cccc(C(C)C)c1OCOP(=O)(O)O
Mol. weight
288.28 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Discontinued

Oral

No

Parenteral

Yes

Topical

No

Prodrug

Sources

Also known as

  • aquavan
  • aquavan
  • aquavan
  • fospropofol
  • fospropofol
  • fospropofol
  • fospropofol
  • fospropofol
  • fospropofol
  • fospropofol
  • fospropofol
  • fospropofol disodium
  • fospropofol disodium
  • fospropofol disodium
  • fospropofol disodium
  • fospropofol disodium
  • fospropofol disodium
  • fospropofol sodium
  • fospropofol sodium
  • fospropofol sodium
  • fospropofol sodium
  • fospropofol sodium
  • gpi15715
  • gpi 15715
  • lusedra
  • lusedra
  • lusedra
  • lusedra
  • lusedra
  • lusedra
  • methanol, (2,6-bis(1-methylethyl)phenoxy)-, dihydrogen phosphate, disodium salt

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06573489Phase 4Sep 15, 2024Huazhong University of Science and Technology
NCT06251999Phase 4Aug 1, 2024Jiao Tong University
NCT06344325Phase 4May 1, 2024Huazhong University of Science and Technology
NCT06261996N/AFeb 12, 2024Henan Provincal People's Hospital
NCT01378754N/AJun 1, 2011University of Kansas
NCT01195103Phase 4Feb 1, 2011Eisai, Mayo Clinic
NCT01289483N/AFeb 1, 2011Eisai, University of Rochester
NCT01308541Phase 1Jan 1, 2011Eisai
NCT01260142Phase 4Nov 1, 2010Eisai
NCT01309984Phase 1Nov 1, 2010Eisai
NCT01401049Phase 4Aug 1, 2010Eisai, New York University
NCT01127438Phase 4Apr 1, 2010Eisai
NCT01271569Phase 1Mar 1, 2010Sichuan University
NCT00327392Phase 2/Phase 3 (Phase 3)May 1, 2006Eisai
NCT00306722Phase 3Apr 1, 2006Eisai
NCT00261599Phase 3Mar 1, 2006Eisai
NCT00125398Phase 2Jul 1, 2005Eisai
NCT00125424Phase 2/Phase 3 (Phase 3)Jul 1, 2005Eisai
NCT00209599Phase 2Feb 1, 2005Covance, Eisai, PPD, Quest Pharmaceutical Services
NCT00209560Phase 3Oct 1, 2004Covance, Eisai, PPD
Showing 20 of 25 trials
Page 1 / 2

Organizations

Research & Development (17)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
EisaiFor profit191652002
PPDFor profit6022002
CovanceFor profit4022004
Bio Analytical Research CorporationFor profit2022003
CaligorRx, Inc.For profit2022003
Huazhong University of Science and TechnologyAcademic/Hospital2212024
MDS PharmaFor profit2022003
Quest Pharmaceutical ServicesFor profit2022004
Henan Provincal People's HospitalAcademic/Hospital1112024
HHI Clinical ResearchFor profit1012003
Jiao Tong UniversityAcademic/Hospital1112024
Mayo ClinicAcademic/Hospital1112011
New York UniversityAcademic/Hospital1112010
Sichuan UniversityAcademic/Hospital1112010
Theorem Clinical ResearchFor profit1012003
University of KansasAcademic/Hospital1112011
University of RochesterAcademic/Hospital1112011
17 organizations
Page 1 / 1

Marketing (2)

OrganizationOrg typeRelationshipDate
EisaiFor profitMKTGDec 8, 2008
EisaiFor profitNDA